Issue 2/2017
A comprehensive analysis of candidate gene signatures in oral squamous cell carcinoma (167 — 174)
DOI: 10.4149/neo_2017_201
Effects of ALA-PDT on HPV16-immortalized cervical epithelial cell (175 — 181)
DOI: 10.4149/neo_2017_202
Association of EGFR and KRAS mutations with expression of p-AKT, DR5 and DcR1 in non-small cell lung cancer (182 — 191)
DOI: 10.4149/neo_2017_203
Cytotoxic effect of oxaloacetate on HepG2-human hepatic carcinoma cells via apoptosis and ROS accumulation (192 — 198)
DOI: 10.4149/neo_2017_204
Microarray analysis of long non-coding RNAs related to microRNA-148b in gastric cancer (199 — 208)
DOI: 10.4149/neo_2017_205
MicroRNA-182 targets FOXF2 to promote the development of triple-negative breast cancer (209 — 215)
DOI: 10.4149/neo_2017_206
Analysis of differentially co-expressed genes based on microarray data of hepatocellular carcinoma (216 — 221)
DOI: 10.4149/neo_2017_207
Mesenchymal stromal cells producing TNFα lack inhibitory effect against A375 experimental lung metastases (222 — 227)
DOI: 10.4149/neo_2017_208
Histone deacetylase inhibitors in plasma cell leukemia treatment: effect of bone marrow microenvironment (228 — 237)
DOI: 10.4149/neo_2017_209
Identification of MAGEA12 as a prognostic outlier gene in gastric cancers (238 — 243)
DOI: 10.4149/neo_2017_210
miR-383 inhibits ovarian cancer cell proliferation, invasion and aerobic glycolysis by targeting LDHA (244 — 252)
DOI: 10.4149/neo_2017_211
Outcome of EGFR inhibitors treatment in advanced NSCLC patients, not enrolled in clinical trials (253 — 261)
DOI: 10.4149/neo_2017_212
Prognostic value of apoptosis inducing factor in uveal melanoma (262 — 268)
DOI: 10.4149/neo_2017_213
New concept of the Axin2 rs2240308 polymorphism and cancer risk: an updated meta-analysis (269 — 277)
DOI: 10.4149/neo_2017_214
Absence of BRAF mutation in pheochromocytoma and paraganglioma (278 — 282)
DOI: 10.4149/neo_2017_215
Prognostic impact of LAT1 and CD98 expression in cutaneous angiosarcoma (283 — 288)
DOI: 10.4149/neo_2017_216
Prognostic significance of MAPK, Topo IIα and E-cadherin immunoexpression in ovarian serous carcinomas (289 — 298)
DOI: 10.4149/neo_2017_217
Cytotoxic T lymphocyte-associated antigen 4 rs231775 polymorphism and osteosarcoma (299 — 304)
DOI: 10.4149/neo_2017_218
DOI: 10.4149/neo_2017_219